60 weeks of ixekizumab effective, well tolerated in moderate-to-severe plaque psoriasis

WASHINGTON – After 60 weeks of continuous therapy with the investigational drug ixekizumab, 722 patients who initially had moderate to severe plaque psoriasis had Psoriasis Area Severity Index (PASI) 75, 90, and 100 response rates of 87%, 78%, and 57%, respectively, based on study results presented...
Source: Skin and Allergy News - Category: Dermatology Source Type: news